<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535843</url>
  </required_header>
  <id_info>
    <org_study_id>2020-999</org_study_id>
    <nct_id>NCT04535843</nct_id>
  </id_info>
  <brief_title>Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China</brief_title>
  <official_title>Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a prospective cohort study aiming to improve the clinical capacity in&#xD;
      the diagnosis and natural history of Chinese patients with myasthenia gravis (MG). 300 MG&#xD;
      patients are planned to recruit, document and prospectively follow up. Management of&#xD;
      screening test and cohort manifestation are studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Myasthenia gravis foundation of America post intervention status</measure>
    <time_frame>3 years</time_frame>
    <description>Myasthenia gravis foundation of America post intervention status (PIS) is assessed by the investigators during follow up. According to history inquiry and physical examination, participants are rated as clinical remission (no complain of myasthenia, no weakness at physical examination, and no therapies concerning MG for one year), pharmocological remission (no complain of myasthenia, no weakness at physical examination, but undertaking MG therapies at the last year), minimal manifestation (no complain of weakness, but showing weakness at physical examination), improvement (symptoms and signs), unchanged (symptoms and signs) , worsening(symptoms and signs), exacerbation(symptoms and signs), and death (medical record).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scores at the follow up</measure>
    <time_frame>Baseline, 1 year, 2 year, and 3 year</time_frame>
    <description>A quantitative MG scoring system (QMG Score) is essential in the objective evaluation of therapy for MG.This scoring system is based on quantitative testing of sentinel muscle groups. Total QMG score range from 0 (extreme disease severity) to 39 (none), higher score indicated less disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Manual Muscle Testing (MMT) Scores at the follow up</measure>
    <time_frame>Baseline, 1 year, 2 year, and 3 year</time_frame>
    <description>The MMT score is the sum of strength or function values assigned by the examining physician to 30 muscle groups usually affected by MG. Total MMT score range from 0 (none) to 124 (extreme muscle weakness), higher score indicated more disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Myasthenia Gravis-Quality of Life Questionnaire-15 item (MG-QOL15) Scores at the follow up</measure>
    <time_frame>Baseline, 1 year, 2 year, and 3 year</time_frame>
    <description>The MG-QOL15 is helpful in informing the clinician about the patient's perception of the extent of and dissatisfaction with MG-related dysfunction. Total MG-QOL15 score range from 0 (none) to 60 (extreme disease severity), higher score indicated more disease severity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>myasthenia gravis</arm_group_label>
    <description>300 MG patients are anticipated for precision diagnosis and disease monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pheripheral biomarkers</intervention_name>
    <description>Detect the pheripheral biomarkers,including lymphocytes and cytokines, in this prospective MG cohort.</description>
    <arm_group_label>myasthenia gravis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood are planned to draw for disease biomarker tests.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from the outpatient clinics and inpatient wards are planned to be enrolled, as&#xD;
        long as meeting the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  fluctuating muscle weakness and fatigability, along with one of the below:&#xD;
&#xD;
          -  more than 10% amplitude decrement in low frequency repetitive nerve stimulation,less&#xD;
             than 10% amplitude increment in high frequency repetitive nerve stimulation;&#xD;
&#xD;
          -  anti-AChR or MuSK antibody positivity;&#xD;
&#xD;
          -  positive to the neostigmine test;&#xD;
&#xD;
          -  understanding and assigning the informed consent form, and having a good compliance&#xD;
             with the follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  excluding the possible diagnosis of Lambert-Eaton syndrome, congenital myasthenia&#xD;
             syndrome,botulism injection, chronic progressive extraocular ophthalmoplegia, etc;&#xD;
&#xD;
          -  participating other clinical trials;&#xD;
&#xD;
          -  poor compliance to the follow up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chongbo Zhao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Huashan Hospital, Shanghai,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chongbo Zhao, MD</last_name>
    <phone>86-021-52889999</phone>
    <email>zhao_chongbo@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changlu Wang, MD</last_name>
      <phone>86-021-22200000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Obsterics and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weirong Gu, MD</last_name>
      <phone>86-021-33189900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenhui Li, MD</last_name>
      <phone>86-021-64931923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chongbo Zhao, MD</last_name>
      <phone>+86 21 52889999</phone>
      <email>zhao_chongbo@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Chongbo Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>myasthenia gravis</keyword>
  <keyword>precision diagnosis</keyword>
  <keyword>antibody detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

